Assembly Biosciences (ASMB)
(Delayed Data from NSDQ)
$19.40 USD
+1.00 (5.43%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $19.45 +0.05 (0.26%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ASMB 19.40 +1.00(5.43%)
Will ASMB be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ASMB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ASMB
Assembly Biosciences (ASMB) Reports Q1 Loss, Tops Revenue Estimates
Amphastar Pharmaceuticals (AMPH) Tops Q1 Earnings Estimates
ASMB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Assembly Biosciences (ASMB) Soars 24.0%: Is Further Upside Left in the Stock?
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
Down -22.6% in 4 Weeks, Here's Why Assembly Biosciences (ASMB) Looks Ripe for a Turnaround
Other News for ASMB
Assembly Biosciences (ASMB) Showcases Promising Herpes Treatment Data
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences presents Phase 1a data for ABI-5366, ABI-1179
Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & ...
Assembly announces first participant dosed in Phase 1b trial of ABI-1179